Multicenter survey of endoscopic treatment of vesicoureteral reflux using polytetrafluoroethylene

Prem Puri, Claudio Granata

Research output: Contribution to journalArticle

Abstract

Purpose: Endoscopic subureteral polytetrafluoroethylene (Teflon) injection has been used successfully to treat primary and secondary vesicoureteral reflux in children. We review the results of subureteral polytetrafluoroethylene injection in terms of its effectiveness, long-term followup and morbidity. Materials and Methods: A total of 53 pediatric urologists and/or pediatric surgeons at 41 centers worldwide answered an inquiry regarding experience with subureteral polytetrafluoroethylene injection in vesicoureteral reflux. Data were collected from a completed standard questionnaire. From 1984 to 1996, 1,921 boys and 6,411 girls with a mean age of 4.5 years (12,251 refluxing ureters) were treated endoscopically with subureteral polytetrafluoroethylene injection. Reflux was grades I to V in 407 (3.3%), 3,832 (31.2%), 5,213 (42.5%), 2,218 (18.1%) and 581 (4.7%) ureters, respectively. In the majority of patients subureteral polytetrafluoroethylene injection was performed on an outpatient basis. Most urologists monitored patients with voiding cystourethrography and renal ultrasound at 3 months, 1 year and 3 years. All patients were followed 1 to 13 years. Results: Reflux resolved in 9,226 ureters (75.3%) after 1 polytetrafluoroethylene injection, in 1,478 (12%) after 2 and in 250 (2%) after 3 or 4. Vesicoureteral reflux improved to grade I after 1 or 2 injections in 743 (6%) ureters, which needed no further treatment. Subureteral injection failed to correct reflux in 554 ureters (4.5%), which were then treated with ureteral reimplantation. Vesicoureteral junction obstruction requiring ureteral reimplantation developed in 41 ureters (0.33%). More than 90% of patients have been followed for more than 2 years. At followup reflux recurred in 326 (2.8%) endoscopically corrected refluxing ureters. No clinically untoward effects were reported in any patient due to the use of polytetrafluoroethylene as an injectable material. Conclusions: The results of this multicenter survey confirm that endoscopic subureteral polytetrafluoroethylene injection is a simple, safe and effective outpatient procedure for treating all grades of vesicoureteral reflux.

Original languageEnglish
Pages (from-to)1007-1011
Number of pages5
JournalJournal of Urology
Volume160
Issue number3 II
DOIs
Publication statusPublished - Sep 1998

Fingerprint

Vesico-Ureteral Reflux
Polytetrafluoroethylene
Ureter
Injections
Therapeutics
Replantation
Outpatients
Surveys and Questionnaires
Pediatrics
Ureteral Obstruction
Morbidity
Kidney

Keywords

  • Endoscopy
  • Injections
  • Polytetrafluoroethylene
  • Ureter
  • Vesico-ureteral reflux

ASJC Scopus subject areas

  • Urology

Cite this

Multicenter survey of endoscopic treatment of vesicoureteral reflux using polytetrafluoroethylene. / Puri, Prem; Granata, Claudio.

In: Journal of Urology, Vol. 160, No. 3 II, 09.1998, p. 1007-1011.

Research output: Contribution to journalArticle

@article{0a16d15ef12f4672b55ece2adaa93956,
title = "Multicenter survey of endoscopic treatment of vesicoureteral reflux using polytetrafluoroethylene",
abstract = "Purpose: Endoscopic subureteral polytetrafluoroethylene (Teflon) injection has been used successfully to treat primary and secondary vesicoureteral reflux in children. We review the results of subureteral polytetrafluoroethylene injection in terms of its effectiveness, long-term followup and morbidity. Materials and Methods: A total of 53 pediatric urologists and/or pediatric surgeons at 41 centers worldwide answered an inquiry regarding experience with subureteral polytetrafluoroethylene injection in vesicoureteral reflux. Data were collected from a completed standard questionnaire. From 1984 to 1996, 1,921 boys and 6,411 girls with a mean age of 4.5 years (12,251 refluxing ureters) were treated endoscopically with subureteral polytetrafluoroethylene injection. Reflux was grades I to V in 407 (3.3{\%}), 3,832 (31.2{\%}), 5,213 (42.5{\%}), 2,218 (18.1{\%}) and 581 (4.7{\%}) ureters, respectively. In the majority of patients subureteral polytetrafluoroethylene injection was performed on an outpatient basis. Most urologists monitored patients with voiding cystourethrography and renal ultrasound at 3 months, 1 year and 3 years. All patients were followed 1 to 13 years. Results: Reflux resolved in 9,226 ureters (75.3{\%}) after 1 polytetrafluoroethylene injection, in 1,478 (12{\%}) after 2 and in 250 (2{\%}) after 3 or 4. Vesicoureteral reflux improved to grade I after 1 or 2 injections in 743 (6{\%}) ureters, which needed no further treatment. Subureteral injection failed to correct reflux in 554 ureters (4.5{\%}), which were then treated with ureteral reimplantation. Vesicoureteral junction obstruction requiring ureteral reimplantation developed in 41 ureters (0.33{\%}). More than 90{\%} of patients have been followed for more than 2 years. At followup reflux recurred in 326 (2.8{\%}) endoscopically corrected refluxing ureters. No clinically untoward effects were reported in any patient due to the use of polytetrafluoroethylene as an injectable material. Conclusions: The results of this multicenter survey confirm that endoscopic subureteral polytetrafluoroethylene injection is a simple, safe and effective outpatient procedure for treating all grades of vesicoureteral reflux.",
keywords = "Endoscopy, Injections, Polytetrafluoroethylene, Ureter, Vesico-ureteral reflux",
author = "Prem Puri and Claudio Granata",
year = "1998",
month = "9",
doi = "10.1016/S0022-5347(01)62683-1",
language = "English",
volume = "160",
pages = "1007--1011",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3 II",

}

TY - JOUR

T1 - Multicenter survey of endoscopic treatment of vesicoureteral reflux using polytetrafluoroethylene

AU - Puri, Prem

AU - Granata, Claudio

PY - 1998/9

Y1 - 1998/9

N2 - Purpose: Endoscopic subureteral polytetrafluoroethylene (Teflon) injection has been used successfully to treat primary and secondary vesicoureteral reflux in children. We review the results of subureteral polytetrafluoroethylene injection in terms of its effectiveness, long-term followup and morbidity. Materials and Methods: A total of 53 pediatric urologists and/or pediatric surgeons at 41 centers worldwide answered an inquiry regarding experience with subureteral polytetrafluoroethylene injection in vesicoureteral reflux. Data were collected from a completed standard questionnaire. From 1984 to 1996, 1,921 boys and 6,411 girls with a mean age of 4.5 years (12,251 refluxing ureters) were treated endoscopically with subureteral polytetrafluoroethylene injection. Reflux was grades I to V in 407 (3.3%), 3,832 (31.2%), 5,213 (42.5%), 2,218 (18.1%) and 581 (4.7%) ureters, respectively. In the majority of patients subureteral polytetrafluoroethylene injection was performed on an outpatient basis. Most urologists monitored patients with voiding cystourethrography and renal ultrasound at 3 months, 1 year and 3 years. All patients were followed 1 to 13 years. Results: Reflux resolved in 9,226 ureters (75.3%) after 1 polytetrafluoroethylene injection, in 1,478 (12%) after 2 and in 250 (2%) after 3 or 4. Vesicoureteral reflux improved to grade I after 1 or 2 injections in 743 (6%) ureters, which needed no further treatment. Subureteral injection failed to correct reflux in 554 ureters (4.5%), which were then treated with ureteral reimplantation. Vesicoureteral junction obstruction requiring ureteral reimplantation developed in 41 ureters (0.33%). More than 90% of patients have been followed for more than 2 years. At followup reflux recurred in 326 (2.8%) endoscopically corrected refluxing ureters. No clinically untoward effects were reported in any patient due to the use of polytetrafluoroethylene as an injectable material. Conclusions: The results of this multicenter survey confirm that endoscopic subureteral polytetrafluoroethylene injection is a simple, safe and effective outpatient procedure for treating all grades of vesicoureteral reflux.

AB - Purpose: Endoscopic subureteral polytetrafluoroethylene (Teflon) injection has been used successfully to treat primary and secondary vesicoureteral reflux in children. We review the results of subureteral polytetrafluoroethylene injection in terms of its effectiveness, long-term followup and morbidity. Materials and Methods: A total of 53 pediatric urologists and/or pediatric surgeons at 41 centers worldwide answered an inquiry regarding experience with subureteral polytetrafluoroethylene injection in vesicoureteral reflux. Data were collected from a completed standard questionnaire. From 1984 to 1996, 1,921 boys and 6,411 girls with a mean age of 4.5 years (12,251 refluxing ureters) were treated endoscopically with subureteral polytetrafluoroethylene injection. Reflux was grades I to V in 407 (3.3%), 3,832 (31.2%), 5,213 (42.5%), 2,218 (18.1%) and 581 (4.7%) ureters, respectively. In the majority of patients subureteral polytetrafluoroethylene injection was performed on an outpatient basis. Most urologists monitored patients with voiding cystourethrography and renal ultrasound at 3 months, 1 year and 3 years. All patients were followed 1 to 13 years. Results: Reflux resolved in 9,226 ureters (75.3%) after 1 polytetrafluoroethylene injection, in 1,478 (12%) after 2 and in 250 (2%) after 3 or 4. Vesicoureteral reflux improved to grade I after 1 or 2 injections in 743 (6%) ureters, which needed no further treatment. Subureteral injection failed to correct reflux in 554 ureters (4.5%), which were then treated with ureteral reimplantation. Vesicoureteral junction obstruction requiring ureteral reimplantation developed in 41 ureters (0.33%). More than 90% of patients have been followed for more than 2 years. At followup reflux recurred in 326 (2.8%) endoscopically corrected refluxing ureters. No clinically untoward effects were reported in any patient due to the use of polytetrafluoroethylene as an injectable material. Conclusions: The results of this multicenter survey confirm that endoscopic subureteral polytetrafluoroethylene injection is a simple, safe and effective outpatient procedure for treating all grades of vesicoureteral reflux.

KW - Endoscopy

KW - Injections

KW - Polytetrafluoroethylene

KW - Ureter

KW - Vesico-ureteral reflux

UR - http://www.scopus.com/inward/record.url?scp=0032323058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032323058&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(01)62683-1

DO - 10.1016/S0022-5347(01)62683-1

M3 - Article

C2 - 9719265

AN - SCOPUS:0032323058

VL - 160

SP - 1007

EP - 1011

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3 II

ER -